Chelsea Therapeutics to Present at the ROTH 23rd Annual OC Growth Stock Conference on Tuesday, March 15, 2011
March 10, 2011 07:00 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., March 10, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the ROTH 23rd Annual OC Growth Stock Conference at 9:00 AM PT on...
Chelsea Therapeutics Reports Fourth Quarter and Full Year 2010 Results
March 02, 2011 16:15 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., March 2, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today reported financial results for the fourth quarter and full year 2010 and will host a...
Chelsea Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2010 Results
February 25, 2011 07:30 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., Feb. 25, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it will release fourth quarter and full year 2010 results after the market...
Chelsea Therapeutics Completes Public Offering of Common Stock
February 24, 2011 16:15 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., Feb. 24, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) has completed its previously announced public offering of common stock and announced that the...
Chelsea Therapeutics Prices Public Offering of Common Stock
February 18, 2011 08:00 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., Feb. 18, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced today that it has priced a public offering of 8.75 million shares of its common...
Chelsea Therapeutics Announces Public Offering of Common Stock
February 17, 2011 16:04 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., Feb. 17, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced today its intention, subject to market and other conditions, to offer $35 million in...
Chelsea Therapeutics to Present at 13th Annual BIO CEO & Investor Conference
February 14, 2011 08:00 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., Feb. 14, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 13th Annual BIO CEO & Investor Conference at 1:30 PM ET on...
Chelsea Therapeutics Announces Interim Results and Plans to Modify Study 306 to Focus on Reduction in Falls Associated With Neurogenic Orthostatic Hypotension
February 02, 2011 07:00 ET
|
Chelsea Therapeutics
Independent Data Monitoring Committee Concludes Continuation of Study Using Subjective OHQ Composite Endpoint Futile While Unblinded Analysis Reveals Robust Efficacy Reflected in Objective Falls...
Chelsea Therapeutics Reports Data Demonstrating Sustained Symptomatic Benefit of Northera in Neurogenic Orthostatic Hypotension Over 12-Month Treatment Period
January 20, 2011 07:00 ET
|
Chelsea Therapeutics
Patients Continue to Report Statistically Significant 2.8 Unit Improvement in OHQ Composite Scores Following 12 Months of Open Label Treatment With Northera (p<0.001)
Parkinson's Disease...
Chelsea Therapeutics Accelerates Northera NDA Filing Following Meeting With FDA
December 20, 2010 06:30 ET
|
Chelsea Therapeutics
Chelsea to File for US Marketing Approval of Northera in Symptomatic Neurogenic Orthostatic Hypotension in Q2 2011 Based on Efficacy Data from Phase III Studies 301 and 302
FDA Will Not...